{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:29:42Z","timestamp":1791430182780,"version":"4.3.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:00:00Z","timestamp":1646438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The aim of this study was to assess the efficacy and adverse effects of methadone when used as first-line therapy in patients that are either receiving low doses of opioids or none.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with advanced cancer were prospectively assessed. Opioid-naive patients (L-group) were started with methadone at 6\u00a0mg\/day. Patients receiving weak or other opioids in doses of &amp;lt;60\u00a0mg\/day of OME (H-group) were started with methadone at 9\u00a0mg\/day. Methadone doses were changed according to the clinical needs to obtain the most favorable balance between analgesia and adverse effects. Edmonton Symptom Asssement Score (ESAS), Memorial Delirium Assessment Score (MDAS), doses of methadone, and the use of adjuvant drugs were recorded before starting the study treatment (T0), 1 week after (T7), 2 weeks after (T14), 1 month after (T30), and 2 months after (T60). Methadone escalation index percent (MEI%) and in mg (MEImg) were calculated at T30 and T60.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-two patients were assessed. In both groups H and L, there were significant changes in pain and symptom intensity at the different times during the study. Adverse effects as causes of drop-out were minimal. Mean MEImg was 0.09 (SD 0.28) and 0.02 (SD 0.07) at T30 and T60, respectively. MEI% was 1.01 (SD 3.08) and 0.27 (SD 0.86) at T30 and T60, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Methadone used as a first-line opioid therapy provided good analgesia with limited adverse effects and a minimal opioid-induced tolerance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyab081","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T20:09:13Z","timestamp":1641240553000},"page":"323-327","source":"Crossref","is-referenced-by-count":28,"title":["Methadone as First-line Opioid for the Management of Cancer Pain"],"prefix":"10.1093","volume":"27","author":[{"given":"Sebastiano","family":"Mercadante","sequence":"first","affiliation":[{"name":"Main Regional Center for Pain Relief & Supportive\/Palliative Care, La Maddalena Cancer center, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Adile","sequence":"additional","affiliation":[{"name":"Main Regional Center for Pain Relief & Supportive\/Palliative Care, La Maddalena Cancer center, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ferrera","sequence":"additional","affiliation":[{"name":"Main Regional Center for Pain Relief & Supportive\/Palliative Care, La Maddalena Cancer center, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"Pallotti","sequence":"additional","affiliation":[{"name":"Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Ricci","sequence":"additional","affiliation":[{"name":"Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Main Regional Center for Pain Relief & Supportive\/Palliative Care, La Maddalena Cancer center, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Casuccio","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"issue":"3","key":"2022040513520111600_CIT0001","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.hoc.2018.01.002","article-title":"Cancer pain syndromes.","volume":"32","author":"Portenoy","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"key":"2022040513520111600_CIT0002","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers11040510","article-title":"Cancer pain assessment and classification.","volume":"11","author":"Caraceni","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2022040513520111600_CIT0003","first-page":"242","article-title":"Managing cancer pain in older adults.","volume":"23","author":"Guerard","year":"2017","journal-title":"Cancer J."},{"issue":"12","key":"2022040513520111600_CIT0004","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.31303","article-title":"Cancer pain management and the opioid crisis in America: how to preserve hard-earned gains in improving the quality of cancer pain management.","volume":"124","author":"Paice","year":"2018","journal-title":"Cancer."},{"issue":"5","key":"2022040513520111600_CIT0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0269216311406313","article-title":"A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project.","volume":"25","author":"King","year":"2011","journal-title":"Palliat Med."},{"issue":"4","key":"2022040513520111600_CIT0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","article-title":"Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract."},{"issue":"3","key":"2022040513520111600_CIT0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.hoc.2018.01.004","article-title":"Methadone: maximizing safety and efficacy for pain control in patients with cancer.","volume":"32","author":"McPherson","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"issue":"8","key":"2022040513520111600_CIT0008","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40263-020-00743-3","article-title":"Methadone for pain management: a pharmacotherapeutic review.","volume":"34","author":"Kreutzwiser","year":"2020","journal-title":"CNS Drugs."},{"issue":"6","key":"2022040513520111600_CIT0009","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","article-title":"Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis.","volume":"122","author":"Higgins","year":"2019","journal-title":"Br J Anaesth."},{"key":"2022040513520111600_CIT0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2015.12.011","article-title":"Opioid switching in cancer pain: from the beginning to nowadays.","volume":"99","author":"Mercadante","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"issue":"3","key":"2022040513520111600_CIT0011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1526-4637.2012.01334.x","article-title":"Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.","volume":"13","author":"Mercadante","year":"2012","journal-title":"Pain Med."},{"issue":"11","key":"2022040513520111600_CIT0012","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00520-004-0650-1","article-title":"Addition of a second opioid may improve opioid response in cancer pain: preliminary data.","volume":"12","author":"Mercadante","year":"2004","journal-title":"Support Care Cancer."},{"issue":"3","key":"2022040513520111600_CIT0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/jpm.2012.0335","article-title":"Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series.","volume":"16","author":"Wallace","year":"2013","journal-title":"J Palliat Med."},{"issue":"6","key":"2022040513520111600_CIT0014","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2011.06.005","article-title":"Use of methadone as a coanalgesic.","volume":"42","author":"McKenna","year":"2011","journal-title":"J Pain Symptom Manage."},{"issue":"9","key":"2022040513520111600_CIT0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/jpm.2015.0525","article-title":"Methadone as a coanalgesic for palliative care cancer patients.","volume":"19","author":"Courtemanche","year":"2016","journal-title":"J Palliat Med."},{"issue":"3","key":"2022040513520111600_CIT0016","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jpainsymman.2017.10.017","article-title":"Methadone as a first-line opioid in cancer pain management: a systematic review.","volume":"55","author":"Mercadante","year":"2018","journal-title":"J Pain Symptom Manage."},{"issue":"11","key":"2022040513520111600_CIT0017","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1007\/s00520-021-06211-y","article-title":"First-line methadone for cancer pain: titration time analysis.","volume":"29","author":"Mammana","year":"2021","journal-title":"Support Care Cancer."},{"issue":"3","key":"2022040513520111600_CIT0018","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton symptom assessment system 25\u00a0years later: past, present, and future developments.","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage."},{"issue":"12","key":"2022040513520111600_CIT0019","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/1097-0142(20000615)88:12<2859::AID-CNCR29>3.0.CO;2-T","article-title":"Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: assessing delirium in advanced cancer.","volume":"88","author":"Lawlor","year":"2000","journal-title":"Cancer."},{"issue":"4","key":"2022040513520111600_CIT0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0885-3924(96)00302-8","article-title":"Monitoring of opioid therapy in advanced cancer pain patients.","volume":"13","author":"Mercadante","year":"1997","journal-title":"J Pain Symptom Manage."},{"issue":"12","key":"2022040513520111600_CIT0021","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1185\/03007995.2010.532545","article-title":"Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.","volume":"26","author":"Mercadante","year":"2010","journal-title":"Curr Med Res Opin."},{"issue":"3","key":"2022040513520111600_CIT0022","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpainsymman.2006.01.001","article-title":"Low morphine doses in opioid-naive cancer patients with pain.","volume":"31","author":"Mercadante","year":"2006","journal-title":"J Pain Symptom Manage."},{"issue":"10","key":"2022040513520111600_CIT0023","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.clinthera.2009.10.013","article-title":"Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.","volume":"31","author":"Mercadante","year":"2009","journal-title":"Clin Ther."},{"key":"2022040513520111600_CIT0024","doi-asserted-by":"crossref","first-page":"593647","DOI":"10.3389\/fphar.2020.593647","article-title":"Morphine antinociception restored by use of methadone in the morphine-resistant inflammatory pain state.","volume":"11","author":"Watanabe","year":"2020","journal-title":"Front Pharmacol."},{"issue":"8","key":"2022040513520111600_CIT0025","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1007\/s00520-016-3191-5","article-title":"Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.","volume":"24","author":"Peirano","year":"2016","journal-title":"Support Care Cancer."},{"issue":"6","key":"2022040513520111600_CIT0026","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1089\/jpm.2012.0612","article-title":"The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia.","volume":"16","author":"Salpeter","year":"2013","journal-title":"J Palliat Med."},{"issue":"2","key":"2022040513520111600_CIT0027","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cncr.24754","article-title":"Methadone initiation and rotation in the outpatient setting for patients with cancer pain.","volume":"116","author":"Parsons","year":"2010","journal-title":"Cancer."},{"issue":"2","key":"2022040513520111600_CIT0028","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/jpm.2019.0253","article-title":"the use of low-dose methadone as add-on to regular opioid therapy in cancer-related pain at end of life: a national swedish survey in specialized palliative care.","volume":"23","author":"F\u00fcrst","year":"2020","journal-title":"J Palliat Med."},{"issue":"6","key":"2022040513520111600_CIT0029","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/oxfordjournals.annonc.a010679","article-title":"Patient-controlled analgesia with oral methadone in cancer pain: preliminary report.","volume":"7","author":"Mercadante","year":"1996","journal-title":"Ann Oncol."},{"issue":"10","key":"2022040513520111600_CIT0030","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.1996.14.10.2836","article-title":"Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients.","volume":"14","author":"De Conno","year":"1996","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022040513520111600_CIT0031","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0885-3924(99)00048-2","article-title":"Methadone response in advanced cancer patients with pain followed at home.","volume":"18","author":"Mercadante","year":"1999","journal-title":"J Pain Symptom Manage."},{"issue":"4","key":"2022040513520111600_CIT0032","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0885-3924(86)80042-2","article-title":"A randomized study on oral administration of morphine and methadone in the treatment of cancer pain.","volume":"1","author":"Ventafridda","year":"1986","journal-title":"J Pain Symptom Manage."},{"issue":"11","key":"2022040513520111600_CIT0033","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1200\/JCO.1998.16.11.3656","article-title":"Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.","volume":"16","author":"Mercadante","year":"1998","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022040513520111600_CIT0034","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejpain.2008.01.013","article-title":"Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.","volume":"12","author":"Mercadante","year":"2008","journal-title":"Eur J Pain."},{"issue":"1","key":"2022040513520111600_CIT0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2004.03.172","article-title":"Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.","volume":"22","author":"Bruera","year":"2004","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022040513520111600_CIT0036","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1185\/03007995.2011.635197","article-title":"Outcome of opioid switching 4 weeks after discharge from a palliative care unit.","volume":"27","author":"Mercadante","year":"2011","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"2022040513520111600_CIT0037","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpainsymman.2013.08.010","article-title":"Factors associated with survival after opioid rotation in cancer patients presenting to an outpatient supportive care center.","volume":"48","author":"Reddy","year":"2014","journal-title":"J Pain Symptom Manage."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/4\/323\/43287356\/oyab081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/4\/323\/43287356\/oyab081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:53:34Z","timestamp":1649166814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/4\/323\/6542924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,5]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,5]]},"published-print":{"date-parts":[[2022,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyab081","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,5]]}}}